ARRB2 and prostate adenocarcinoma: Subsequently, we divided the PRAD patient samples into the ARRB2 high group and low group (Figure 6(e)) and found that the PRAD patients in the ARRB2 high group had a poorer prognosis, with a median time of 5.8 years and an HR of 2.206 (>1), indicating that ARRB2 was a risk factor for PRAD prognosis (Figure 6(f)).